<DOC>
	<DOCNO>NCT00006760</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ifosfamide vinorelbine , work different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat child refractory relapse Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Refractory Relapsed Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate ( overall within stratum ) minimally pretreated , low-risk heavily pretreated , high-risk child refractory relapse Hodgkin 's lymphoma treat ifosfamide vinorelbine filgrastim ( G-CSF ) . - Determine cardiac , hepatic , renal , hematologic toxicity regimen minimally-pretreated , low-risk patient . - Determine toxic death rate minimally pretreated , low-risk patient treat regimen . - Determine whether treatment regimen mobilize sufficient hematopoietic stem cell ( CD34 ) subsequent stem cell transplantation minimally pretreated , low-risk patient . - Determine incidence hypermutability longitudinal genotoxic biomonitoring patient treated regimen . - Determine prognostic significance biological marker , include serum interleukin ( IL ) -10 receptor , serum IL-2 receptor , p53 , mdm-2 patient treat regimen . OUTLINE : This multicenter study . Patients stratify prior therapy ( minimally pretreated , low-risk v heavily pretreated , high-risk ) . Patients receive ifosfamide IV 24 hour day 1-4 vinorelbine IV 6-10 minute day 1 5 . Patients also receive filgrastim ( G-CSF ) subcutaneously IV 15-30 minute begin 24-36 hour completion vinorelbine continue daily blood count recover . Treatment repeat least every 21 day 2 course absence disease progression unacceptable toxicity . Patients may receive third course therapy discretion investigator . Heavily pretreated , high-risk patient achieve complete response eligible stem cell transplantation . Patients undergo peripheral blood stem cell ( PBSC ) collection hematopoietic recovery second course chemotherapy . Patients sufficient PBSCs collect may undergo PBSC transplantation protocol COG-AHOD0121 . Patients follow 1 , 6 , 12 month periodically thereafter . PROJECTED ACCRUAL : A total 66 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm refractory relapse Hodgkin 's lymphoma Mixed cellularity , otherwise specify ( NOS ) Lymphocytic depletion , NOS Lymphocytic depletion , diffuse fibrosis Lymphocytic depletion , reticular Lymphocytic predominance , NOS Lymphocytic predominance , diffuse Lymphocytic predominance , nodular Hodgkin 's paragranuloma NOS Hodgkin 's granuloma Hodgkin 's sarcoma Nodular sclerosis , NOS Nodular sclerosis , cellular phase Nodular sclerosis , lymphocytic predominance Nodular sclerosis , mixed cellularity Nodular sclerosis , lymphocytic depletion Other ( type specify ) In first relapse Metastasis bone marrow granulocytopenia , anemia , and/or thrombocytopenia allow Not enrol POG9426 unless extranodal site recurrence PATIENT CHARACTERISTICS : Age : Under 30 diagnosis Performance status : Lansky 60100 % ( patient 16 year ) Karnofsky 60100 % ( patient 16 year ) Life expectancy : At least 2 month Hematopoietic : See Disease Characteristics Absolute neutrophil count least 1,000/mm^3 Platelet count least 75,000/mm^3 ( transfusion independent ) Hepatic : Bilirubin great 1.5 time normal SGOT SGPT less 2.5 time normal Renal : Creatinine great 1.5 time normal Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Cardiovascular : Shortening fraction least 27 % echocardiogram OR Ejection fraction least 50 % gate radionuclide Other : No concurrent serious illness No known hypersensitivity E. coliderived protein , filgrastim ( GCSF ) , component study drug PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunomodulating agent Chemotherapy : At least 2 week since prior chemotherapy ( 3 week nitrosoureas ) recover No concurrent anticancer chemotherapy Endocrine therapy : No concurrent steroids No concurrent corticosteroid ( e.g. , dexamethasone ) Radiotherapy : Recovered prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>childhood lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>childhood lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>childhood nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
</DOC>